Liver function: SGOT and SGPT are less than 1.5 times the normal value; bilirubin is less than 1.5mg/dL
Renal function: creatinine \<1.8mg/dL Others: non-pregnant or breast-feeding women; no other malignant diseases (except for non-melanoma or cervical carcinoma in situ) within 5 years or during the same period; no mental illness that causes the inability to obtain informed consent; no other serious diseases that can shorten the survival time disease.
Have not received rectal surgery in the past;
Have not received chemotherapy or radiotherapy in the past;
Have not received biological treatment in the past;
Past endocrine therapy: unlimited.
You may not be if
Rectal cancer with unstable microsatellite (MSI or dMMR);
Preoperative biopsy of tumor immunohistochemistry TPS≤1% or CPS≤1
Known history of human immunodeficiency virus (HIV) or chronic hepatitis B or C (high copy viral DNA);
Autoimmune diseases;
Other active clinical serious infections (\>NCI-CTC version 3.0);
Patients in clinical phase I;
There is evidence that there is distant metastasis before surgery;
Cachexia, decompensation of organ function;
Have a history of pelvic or abdominal radiotherapy;
Multiple primary cancers;
Patients who need treatment for seizures (such as steroids or anti-epileptic treatment);
Have a known additional malignant tumors within 5 years. Exceptions include basal cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer;
Drug abuse and medical, psychological or social conditions may interfere with patients' participation in research or have an impact on the evaluation of research results;
Known or suspected to be allergic to the study drug or to any drug given in connection with this test;
Any unstable conditions or situations that may endanger patient safety and compliance
Clareo Health | PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer
